Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Arovella Therapeutics - Quarterly Appendix 4C and Activities Report (ASX:ALA)

PERTH, AUSTRALIA 31 January 2022: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery ...read more

Arovella Therapeutics Completes $4.57M Placement & Launches $1.5M SPP (ASX:ALA)

Firm commitments received for $4.57 million Placement to new and existing institutional and sophisticated investors at $0.038 per share The Placement includes cornerstone participation by Merchan...read more

Arovella Therapeutics - SPP Offer Booklet (ASX:ALA)

On behalf of the board of Arovella Therapeutics Limited ACN 090 987 250 (ASX: ALA) (ALA or Company), we are pleased to offer you the opportunity to purchase up to $30,000 in additional shares in ALA...read more

Arovella Therapeutics - Trading Halt (ASX:ALA)

The securities of Arovella Therapeutics Limited (‘ALA’) will be placed in trading halt at the request of ALA, pending it releasing an announcement. Unless ASX decides otherwise, the secu...read more

Arovella Therapeutics - AGM FY21 Presentation (ASX:ALA)

To view the presentation, download the attached PDF.

Arovella Therapeutics licences novel monoclonal antibody from MD Anderson (ASX:ALA)

Arovella has acquired from MD Anderson an exclusive global licence to the patent rights for a monoclonal antibody (mAb) that targets a DKK1 peptide The technology can be used as a Chimeric Antige...read more

Arovella Therapeutics - R&D Tax Incentive refund received (ASX:ALA)

Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform and its oral spray delivery technology to treat cancer and con...read more

Arovella Therapeutics - Quarterly Appendix 4C and Activities Report (ASX:ALA)

SUDA Pharmaceuticals - Chile Ministry of Health Approval Granted for ZolpiMist (ASX:ALA)

Chile approval achieved for SUDA’s ZolpiMist® This approval enables ZolpiMist to be marketed in Chile by SUDA’s partner, Teva Pharmaceuticals This is the first of Teva’s t...read more

SUDA Pharmaceuticals - GM presentation (ASX:ALA)

To view the presentation, download the attached PDF.

SUDA Pharmaceuticals - Investor Presentation (ASX:ALA)

To view the presentation, download the attached PDF.

SUDA Pharmaceuticals - Preliminary Final Report (ASX:ALA)

To view the report, download the attached PDF.

SUDA Pharmaceuticals - Dr Reuben Benjamin Appointed to SUDA iNKT Cell Therapy SAB (ASX:ALA)

SUDA enhances its Scientific Advisory Board (SAB) to gain expert guidance on the clinical development of allogenic cell therapies Dr Reuben Benjamin, who leads the plasma cell disorder service an...read more

SUDA Pharmaceuticals signs Licence and Distribution Agreement with STADA (ASX:ALA)

SUDA grants an exclusive Licence for the rights to ZolpiMist® for commercialisation in Australia to STADA Pharmaceuticals, part of the international Pharmaceutical Company, STADA Group SUDA t...read more

SUDA Pharmaceuticals - ZolpiMist Update (ASX:ALA)

SUDA Pharmaceuticals Ltd (ASX: SUD), a biotechnology company focused on developing therapies to treat cancer and conditions that affect the central nervous system, advises that Mitsubishi Tanabe Pha...read more

Viewing: 46 - 60 of 200 Previous | Next